


1/10



**Fig. 1** Anti-PT Results

2/10




Fig. 2 Anti-FHA Results






Fig. 3 Anti-PRN Results

4/10




**Fig.4** Anti-PT Results  
Pre-and Post-Serum Antibody Responses Following Immunization  
With SB "Monovalent" Pa - AAPT, 1996



**Fig. 5** Anti-FHA Results  
Pre-and Post-Serum Antibody Responses (Cont.) AAPT, 1996

6/10



**Fig. 6** Anti-PRN Results

Pre-and Post-Serum Antibody Responses (Cont.) AAPT, 1996

7/10

Pain	dtpa	dT
≤ 48 h	58	60
15 days	60	60
Severe	0	0
<b>Redness</b>		
≤ 48 h	30	37
15 days	30	37
> 20 MM	17	20
<b>Swelling</b>		
≤ 48 h	30	37
15 days	30	37
> 20MM	5	8.3
<b>Fever</b>		
≤ 48 h	7	7
15 days	8	8
> 39°C	0	0

**Fig. 7** % Reporting  
dtpa 005 - Reactogenicity

Anti-D	dtpa	dT
Pre		
≥ 0.1	44%	44%
Post		
≥ 0.1	80%	78%
GMT	0.85	0.81
<b>Anti-T</b>		
Pre		
≥ 0.1	88%	88%
Post		
≥ 0.1	97%	100%
GMT	7.37	13.6

**Fig. 8** dtpa 005

SUBSTITUTE SHEET (RULE 26)

T09040" 58/22350

8/10

	Pain Week1	Moderate Pain Week 1	Erythema Week 1	Pain Weeks 2-4	Erythema Weeks 2-4
SB-Med (N=31)	90	10	10	17	3
Placebo (N=31)	19	3	3	3	0

- No serious adverse events
- No severe pain
- 2 subjects with hives (days 1-4; days 18-22)

**Fig. 9** % Reporting  
AAPT- Reactogenicity

Pain	dtpa	dT
≤ 48 h	69	70
15 days	69	70
Severe	0	1
<b>Redness</b>		
≤ 48 h	12	20
15 days	12	20
> 30 MM	1	9
<b>Swelling</b>		
≤ 48 h	12	28
15 days	13	30
> 30MM	7	15
<b>Fever</b>		
≤ 48 h	5	6
15 days	13	15
> 39°C	0	1

**Fig. 10** % Reporting  
dtpa 003 - Reactogenicity  
SUBSTITUTE SHEET (RULE 26)




9/10

Anti-D	dtpa	dT
Pre		
$\geq 0.1$	72%	72%
Post		
$\geq 0.1$	100%	100%
GMT	3.3	10.5


  

Anti-T		
Pre		
$\geq 0.1$	94%	99%
Post		
$\geq 0.1$	100%	100%
GMT	22.9	54.5


**Fig. 11** Antibody responses dtpa 003



**Fig. 12** Anti-PT Results  
SUBSTITUTE SHEET (RULE 26)



**Fig. 13** Anti-FHA Results



**Fig. 14** Anti-PRN Results  
SUBSTITUTE SHEET (RULE 26)